
==== Front
BMC Pulm Med
BMC Pulm Med
BMC Pulmonary Medicine
1471-2466
BioMed Central London

39238010
3254
10.1186/s12890-024-03254-9
Research
Quantitative CT analysis of idiopathic pulmonary fibrosis and correlation with lung function study
Zhang Hongmei
Li Xinyi
Zhang Xiaoyue
Yuan Yu
Zhao Chenglei
Zhang Jinling jinlingzi@163.com

https://ror.org/03s8txj32 grid.412463.6 0000 0004 1762 6325 Department of Radiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150000 China
5 9 2024
5 9 2024
2024
24 43711 6 2024
29 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Idiopathic Pulmonary Fibrosis (IPF) is a progressive fibrotic lung disease. However, the field of quantitative CT scan analysis in conjunction with pulmonary function test for IPF patients remains relatively understudied. In this study, we evaluated the diagnostic value of features derived high-resolution computed tomography (HRCT) for patients with IPF and correlated them with pulmonary function tests.

Methods

We retrospectively analyzed the chest HRCT images and pulmonary function test results of 52 patients with IPF during the same period (1 week) and selected 52 healthy individuals, matched for sex, age, and body mass index (BMI) and with normal chest HRCT as controls. HRCT scans were performed using a Philips 256-row Brilliance iCT scanner with standardized parameters. Lung function tests were performed using a Jaeger volumetric tracer for forced vital capacity (FVC), total lung capacity (TLC), forced expiratory volume in first second (FEV1), FEV1/FVC, carbon monoxide diffusing capacity (DLCO), and maximum ventilation volume (MVV) metrics. CT quantitative analysis, including tissue segmentation and threshold-based quantification of lung abnormalities, was performed using 3D-Slicer software to calculate the percentage of normal lung areas (NL%), percentage of ground-glass opacity areas (GGO%), percentage of fibrotic area (F%) and abnormal lesion area percentage (AA%). Semi-quantitative analyses were performed by two experienced radiologists to assess disease progression. The aortic-to-sternal distance (ASD) was measured on axial images as a standardized parameter. Spearman or Pearson correlation analysis and multivariate stepwise linear regression were used to analyze the relationship between the data in each group, and the ROC curve was used to determine the optimal quantitative CT metrics for identifying IPF and controls.

Results

ROC curve analysis showed that F% distinguished the IPF patient group from the control group with the largest area under the curve (AUC) of 0.962 (95% confidence interval: 0.85–0.96). Additionally, with F% = 4.05% as the threshold, the Youden’s J statistic was 0.827, with a sensitivity of 92.3% and a specificity of 90.4%. The ASD was significantly lower in the late stage of progression than in the early stage (t = 5.691, P < 0.001), with a mean reduction of 2.45% per month. Quantitative CT indices correlated with all pulmonary function parameters except FEV1/FVC, with the highest correlation coefficients observed for F% and TLC%, FEV1%, FVC%, MVV% (r = − 0.571, − 0.520, − 0.521, − 0.555, respectively, all P-values < 0.001), and GGO% was significantly correlated with DLCO% (r = − 0.600, P < 0.001). Multiple stepwise linear regression analysis showed that F% was the best predictor of TLC%, FEV1%, FVC%, and MVV% (R2 = 0.301, 0.301, 0.300, and 0.302, respectively, all P-values < 0.001), and GGO% was the best predictor of DLCO% (R2 = 0.360, P < 0.001).

Conclusions

Quantitative CT analysis can be used to diagnose IPF and assess lung function impairment. A decrease in the ASD may indicate disease progression.

Keywords

Idiopathic pulmonary fibrosis
Quantitative CT
Pulmonary function test
Quantitative analysis
Beijing Kanghua Traditional Chinese and Western Medicine Development FoundationNo. KH–2022–DXJJ–022 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Idiopathic pulmonary fibrosis (IPF) is an unexplained, irreversible, chronic, progressive interstitial lung disease characterized by a progressive decline in lung function for which there is a lack of effective treatment and a low survival rate [1, 2]. The prevalence of IPF is increasing in elderly patients, with a median survival of 3–5 years, and high-resolution CT (HRCT) is the most accurate test for noninvasive diagnosis of IPF [3]. IPF manifests as usual interstitial pneumonia (UIP) on HRCT images or surgical lung biopsy [4].

Lung function can reflect the disease progression of patients with IPF, assess the severity of the disease, and predict the disease prognosis. However, pulmonary function tests require the active cooperation of patients [5]. In the process of testing, test results are seriously affected when patients do not cooperate for personal reasons. For patients with serious conditions, it may even be impossible to complete the pulmonary function test. Therefore, qualified pulmonary function tests are not applicable to elderly patients who cannot cooperate and those with acute exacerbation or an advanced stage of IPF.

With the advent of new computer technologies, quantitative CT techniques are developing into viable tools. Quantitative chest CT technology, which allows chest CT images to be reconstructed and calculated by appropriate software, is gradually gaining wide acceptance due to its objectivity and ability to reflect histological features, and has great potential in the assessment of interstitial lung diseases such as IPF [6]. However, few previous studies have performed quantitative CT analysis of IPF to study its relationship with lung function, and most studies are based on visual analysis [7]. Therefore, in this study, we assessed the relationship between quantitative CT analysis of IPF and lung function to determine the value of quantitative CT analysis in predicting lung function impairment in patients with IPF and its clinical application.

Materials and methods

We collected 75 consecutive cases of IPF between February 2021 and February 2024. All patients met the 2018 ATS/ERS/JRS/ALAT guidelines for the diagnosis of IPF. Ultimately, we included 52 patients who underwent pulmonary function tests and high-resolution CT scans within no more than one week between the two tests (Fig. 1). Forty-eight of these patients were diagnosed after multidisciplinary consultation, and four patients had their diagnosis confirmed by surgical lung biopsy. Additionally, 52 healthy individuals matched for sex, age, and body mass index (BMI), and with normalities on chest HRCT were selected as a control group.

Fig. 1 Flow chart depicting the selection process for the final study cohort

The study received approval from the Hospital’s Ethics Committee (Ethics No. YJSKY2023-297). All clinical data were securely extracted from the electronic medical records, ensuring patient confidentiality and compliance with ethical standards.

CT methods

CT scans were performed using a Philips 256-row Brilliance iCT scanner, and all patients underwent respiratory training before scanning, followed by HRCT scanning with breath-holding at the end of maximal inspiration. The patients were placed in the supine position with their hands raised, and the scan was performed from the base of the lungs to the apices. The scanning parameters were as follows: layer thickness, 1 mm; layer spacing, 5 mm; voltage, 120 kV; pitch array, 512 × 512; bone algorithm reconstruction; lung window observation window width, 1,500 Hu, and window position − 600 HU.

Quantitative CT methods

Lung parenchyma segregation was performed using the open source software 3D-Slicer, which automatically segregates the lung parenchyma and manually corrects areas that are inaccurately identified by the software. Images were analyzed by two experienced chest radiologists. Threshold segmentation was used to obtain quantitative CT metrics, setting whole lung pixels between − 1024 and − 200 HU, normal lung tissue pixels between − 950 and − 700 HU, ground-glass opacity pixels between − 700 and − 500 HU, and fibrotic area pixels between − 500 and − 200 HU. The ratios of normal lung pixels, ground-glass opacity pixels, and fibrotic region pixels to whole lung pixels were set as a percentage of normal lung region (NL%), percentage of ground-glass opacity region (GGO%), and percentage of fibrotic region (F%). The sum of the percentage of ground-glass opacity region and the fibrotic region was set as the percentage of abnormal lesion region (AA%) (Fig. 2).

Fig. 2 Male patient with IPF, aged 46. (A) Chest HRCT scan demonstrates bilateral ground-glass opacity and reticular patterns, typical for IPF; (B) Automatic segmentation with 3D-Slicer software, where blue represents normal lung tissue, orange indicates ground-glass opacity areas, pink denotes fibrotic regions, and red signifies blood vessels

Semi-quantitative analysis

Thirty-three of the 52 patients underwent regular CT follow-up. Baseline and follow-up CT scans are spaced 1 to 14 months apart. To assess the progression of fibrosis on CT, the follow-up CT images were simultaneously compared by two experienced radiologists who were blinded to the chronological order of the scans. The images were visually analyzed, and disease progression was defined as a decrease in lung volume and an increase in associated signs, such as tractional bronchiectasis, honeycomb, and ground-glass opacity. The final visual analysis screened 22 patients consistent with disease progression.

Data measurement methods

The ASD is defined as the distance from the anterior wall of the aorta to the posterior wall of the sternum on axial films. This parameter was measured by two experienced chest radiologists at baseline and follow-up CT. The HRCT images were standardized using the pulmonary trunk as an anatomical landmark (Fig. 3).

Fig. 3 Male patient with IPF, aged 46. Baseline (A) and follow-up (B) images show mild progression of fibrosis and a reduction in ASD

Pulmonary function test

Pulmonary function tests were performed using a volumetric tracer from Jeager, Germany, to obtain the main indices of the study cases in this group: forced vital capacity (FVC), total lung volume (TLC), forced expiratory volume in the first second (FEV1), FEV1/FVC, diffusion volume (DLCO), and maximum ventilation volume (MVV). The pulmonary function tests were performed with the subject in the sitting position, and the best result of three repeated measurements was taken as the final result.

Statistical methods

The Shapiro–Wilk method was used to test the normality of the measurement data, with normally distributed data expressed as the mean ± standard deviation and non-normally distributed data expressed as M (P25–P75). Correlations between quantitative CT indices and lung function parameters were assessed using Spearman or Pearson correlation analysis. The diagnostic efficacy of quantitative CT indices for IPF was assessed using subject operating characteristic curves, and the optimal thresholds, the Youden’s J statistic, sensitivity, specificity, and area under the curve (AUC) were calculated. Multiple stepwise linear regression analyses were used to determine the optimal CT quantitative index for predicting lung function. Differences were considered statistically significant at P < 0.05. Statistical analyses were performed using SPSS 26.0.

Results

Study population

Fifty-two patients who underwent pulmonary function tests and HRCT within 1 week and 52 healthy patient controls were included. Data relating to age, sex, BMI, smoking status, ASD, quantitative chest CT, and pulmonary function are shown in Table 1. Differences between the two groups in terms of sex composition ratio, age, and BMI were not statistically significant. There was a significantly larger number of smokers among the patients in the IPF group than in the control group (P < 0.05). The ASD was significantly higher in the healthy control group (P < 0.05). CT quantitative indices showed that the NL% was significantly lower in the IPF group than in the healthy control group, and GGO%, F%, and AA% were significantly higher in the IPF group than in the control group (P < 0.001). Of the 33 patients followed up, 11 showed no evidence of progressive fibrosis. Follow-up CT scans did not show any reduction in fibrosis in the 33 patients.

Table 1 Comparison of relevant characteristics between the IPF patient group and the healthy control group

Characteristics	IPF group	control group	P value	
Sex (Male: Female)	30:22	30:22	1.000	
Age (y)	63.91 ± 9.44	62.79 ± 8.11	0.498	
BMI (kg/m2)	24.03 ± 2.80	23.81 ± 2.79	0.690	
Smoking (Y/N)	19:33	7:45	0.007	
ASD	22.57 ± 7.58	26.14 ± 6.78	0.013	
FEV1 (%)	78.55 ± 15.79	-	-	
FVC (%)	75.90 ± 15.67	-	-	
FEV1/FVC (%)	87.50 ± 9.20	-	-	
TLC (%)	68.04 ± 14.05	-	-	
DLCO (%)	45.83 ± 16.94	-	-	
MVV (%)	65.88 ± 16.54	-	-	
NL (%)	59.82 ± 8.01	64.00(61.00 ~ 67.75)	< 0.001	
GGO (%)	14.98 ± 5.10	6.45(5.15 ~ 8.40)	< 0.001	
F (%)	8.00(6.03 ~ 10.75)	3.15(2.70 ~ 3.70)	< 0.001	
AA (%)	23.40 ± 8.16	9.85(8.70 ~ 12.00)	< 0.001	
Data are expressed as mean ± standard deviation or median (quartiles). BMI, ASD, FEV1, FVC, TLC, DLCO and MVV represent body mass index, aortic sternal distance, forced expiratory volume in first second, forced vital capacity, total lung capacity, carbon monoxide diffusing capacity and maximum ventilation volume.NL, GGO, F and AA represent normal lung region, ground-glass opacity region, fibrotic region and abnormal lesion area

Comparison and correlation analysis of smoking in IPF group and healthy controls

The IPF group contained significantly more smokers than in the control group (P < 0.05), and there was a significant positive correlation with morbidity (P < 0.05) (Table 2).

Table 2 Correlation analysis of smoking in IPF group and healthy controls

	r s	P value	
Smoking	0.266	0.006	

Comparison of aortic-to-sternal distance before and after disease progression in patients with IPF

As shown in Table 3, the ASD was significantly lower in the late stage of progression than in the early stage (t = 5.691, P < 0.001), with an average monthly reduction of 2.45%.

Table 3 ASD changes in IPF patients pre- and post-disease progression

	Pre-process	Post-process	t	P Value	
ASD	22.57 ± 7.35	20.40 ± 7.49	5.691	< 0.001	
ASD represents the aortic-to-sternal distance

ROC curve analysis results

The CT quantitative indexes NL%, GGO%, F%, and AA% were used as diagnostic indexes to classify patients with IPF and healthy controls according to the ROC curve. The results showed that the F% discriminated between the two groups, with the largest AUC of 0.962 (95% confidence interval: 0.925 ~ 0.998), and the Youden’s J statistic with a threshold value of F% = 4.05% was 0.827, with a sensitivity of 92.3% and specificity of 90.4% (Fig. 4; Table 4).

Table 4 ROC curve analysis

QCT variable	AUC	P Value	J	Sensitivity	Specificity	95%CI	
NL%	0.703	< 0.001	0.385	0.423	0.965	0.601 ~ 0.806	
GGO%	0.935	< 0.001	0.730	0.942	0.788	0.889 ~ 0.908	
F%	0.962	< 0.001	0.827	0.923	0.904	0.952 ~ 0.998	
AA%	0.950	< 0.001	0.808	0.904	0.904	0.907 ~ 0.992	
NL, GGO, F and AA represent normal lung region, ground-glass opacity region, fibrotic region and abnormal lesion area. AUC represents area under the curve. J represents Youden’s J statistic. CI represents confidence interval

Fig. 4 Quantitative CT metrics for discriminating IPF patients from controls using ROC analysis

Correlation between quantitative chest CT indices and lung function in patients with IPF

As shown in Table 5, the correlations between quantitative CT indices and pulmonary function parameters beyond the initial FEV1/FVC were statistically significant, with the highest correlation coefficients between F% and TLC%, FEV1%, FVC%, MVV% (r = − 0.571, − 0.520, − 0.521, − 0.555, P-values < 0.001). GGO% was significantly correlated with DLCO% (r = − 0.600, P < 0.001).

Multiple stepwise first regression analyses were performed to determine whether lung function indices could be predicted from quantitative CT analysis data. F% was the best predictor of TLC%, FEV1%, FVC%, and MVV% (R2 = 0.301, 0.301, 0.300, and 0.302, all P-values < 0.001), while GGO% was the best predictor of DLCO% (R2 = 0.360, P < 0.001) (Table 6).

Table 5 Analysis of the correlation between quantitative chest CT indices and Pulmonary function in patients with IPF

Characteristics	FEV1%	FVC%	FEV1/FVC%	TLC%	DLCO%	MVV%	
r	p	r	p	r	p	r	p	r	p	r	p	
NL%	0.410	0.003	0.398	0.004	-0.138	0.329	0.400	0.003	0.453	< 0.001	0.352	0.011	
GGO%	-0.455	< 0.001	-0.446	< 0.001	-0.028	0.842	-0.494	< 0.001	-0.600	< 0.001	-0.393	0.004	
F%	-0.520	< 0.001	-0.521	< 0.001	0.104	0.465	-0.571	< 0.001	-0.564	< 0.001	-0.555	< 0.001	
AA%	-0.513	< 0.001	-0.506	< 0.001	0.007	0.958	-0.537	< 0.001	-0.598	< 0.001	-0.474	< 0.001	
FEV1, FVC, TLC, DLCO and MVV represent forced expiratory volume in first second, forced vital capacity, total lung capacity, carbon monoxide diffusing capacity and maximum ventilation volume. NL, GGO, F and AA represent normal lung region, ground-glass opacity region, fibrotic region and abnormal lesion area

Table 6 Optimal CT predictors of lung function via stepwise regression

PFT	QCT variable	β Coefficient	Model R2	t	P Value	
FEV1%	F%	-0.549	0.301	-4.641	< 0.001	
FVC%	F%	-0.548	0.300	-4.628	< 0.001	
TLC%	F%	-0.549	0.301	-4.640	< 0.001	
DLCO%	GGO%	-0.600	0.360	-5.308	< 0.001	
MVV%	F%	-0.549	0.302	-4.649	< 0.001	
PFT represents pulmonary function test. FEV1, FVC, TLC, DLCO and MVV represent forced expiratory volume in first second, forced vital capacity, total lung capacity, carbon monoxide diffusing capacity and maximum ventilation volume. GGO and F represent ground-glass opacity region and fibrotic region

Discussion

Currently, there is no consensus on the threshold definition; however, most scholars now recognize the idea that − 950 to − 700 HU is a normal lung pixel [8]. Stefano et al. [9]. found that the optimal upper lung threshold CT value for the diagnosis of IPF was − 200 HU by comparing the diagnostic values of − 200 HU, 0, and 200 HU as the upper threshold for IPF. Ash et al. [10]. considered that the lung volume should be from − 1024 to − 200 HU. Matsuoka et al. [11]. have defined the extent of interstitial lung disease as areas of high attenuation by selecting a rage from − 700 to 0 HU. In their study, they found that the range of − 500 HU to 0 HU has a higher correlation with fibrosis, and the lung attenuation in the range of − 700 to − 500 HU is strongly correlated with the extent of ground-glass opacity. Therefore, we set the whole lung pixels between − 1024 and − 200 HU, normal lung tissue pixels between − 950 and − 700 HU, ground-glass opacity pixels between − 700 and − 500 HU, and fibrotic region pixels between − 500 and − 200 HU.

Early diagnosis of IPF is critical to patient prognosis. Currently, the diagnosis of IPF relies on HRCT, pathology, and pulmonary function tests. Oldham et al. [12] noted that patients with IPF usually received a correct diagnosis after seeing multiple doctors and waiting more than a year. In another study [13], they found that the time between the onset of symptoms and obtaining a confirmed diagnosis in patients with IPF was usually between 4 and 5 years. Overall, our findings and the cited studies suggest that it is crucial to make a correct diagnosis of IPF as early as possible. HRCT is the most meaningful test for the diagnosis of IPF. HRCT can be used to visualize abnormal lung changes. This study shows that the CT quantitative index F% value of 4.05% is the best threshold value to identify IPF in healthy controls. In healthy controls, the CT quantitative index was mainly related to the fallout effect. Ostridge et al [14] performed quantitative CT analysis on subjects with normal lung function and found that emphysema may also occur in people with normal lung function. Therefore, when the F% of patients is higher than 4.05%, it is clinically advisable to be vigilant for the possibility of interstitial lung disease, with a higher likelihood of IPF.

PFT is important for assessing disease severity and predicting the risk of disease exacerbation or death in patients with interstitial lung disease [15]. A decrease in lung function, especially FVC, has been shown to be significantly associated with an increased risk of death in IPF [16], and the guidelines [17] also suggest that lung function is an important method for assessing the disease progression and predicting the disease prognosis in IPF. The results of the present study showed that CT quantitative indices correlated with lung function parameters except FEV1/FVC. FEV1/FVC is used to assess airflow obstruction in COPD and correlates with emphysema parameters analyzed by CT quantitative analysis [18], whereas IPF usually manifests itself as a restrictive ventilatory disorder, which may be the reason why it did not correlate with CT quantitative indices in the present study. Koh et al. [19] found that changes in CT quantification and FVC were related to visual assessment of interstitial lung disease progression by deep learning. A related study [20] found that FVC reliably predicted mortality in patients with IPF. In this study, the relationship between CT quantitative indexes and each lung function parameter was analyzed by modeling separately. The results showed that F% was the best predictor of FVC%, and GGO% was the best predictor of DLCO%, which indicated that CT quantitative analysis could assess lung function impairment to a certain extent and could be used as a supplement to pulmonary function tests. The accuracy of PFT depends on the patient’s own cooperation, whereas HRCT requires much less patient cooperation than PFT. Therefore, quantitative CT analysis may be more useful when the patient is in poor physical condition or has poor cooperation. Quantitative CT analysis allows not only for specific quantification of the percentage of each lesion in the lungs but also for assessment of lung function impairment.

The most commonly used lung function parameters for prognostic and outcome assessment of interstitial lung disease are FVC% and DLCO%. Andersson et al. [21]. found a significant correlation between the degree of interstitial lung disease assessed by HRCT via FVC% and DLCO% in patients with anti-synthetase syndrome, but not with disease staging. This suggests that FVC% and DLCO% are appropriate outcome measures for assessing ILD associated with antisynthetase syndrome. Du et al. [22]. found that fibrotic area percentage and DLCO% were significantly associated with survival. Our results showed that CT quantitative indices correlated with both FVC% and DLCO%, with the highest correlation coefficients observed between F% and FVC% and between GGO% and DLCO%; therefore, we hypothesize that CT quantification is also suitable for prognostic and efficacy assessment in IPF.

Harmful substances in cigarettes such as nicotine, which promotes alveolar epithelial and vascular endothelial damage, play a key role in the evolution of fibrosis [23]. In this study, smoking was found to be positively correlated with the prevalence of the disease (P < 0.05); however, the correlation was weak (r = 0.266), suggesting that smoking is a possible pathogenetic factor in patients with IPF.

The research area of exploring quantifiable indicators of lung volume loss that can be used as routine imaging tools to monitor disease progression is both attractive and promising. The development of such a biomarker would not only provide clinicians with an easier and more direct means to assess the extent of lung disease but also help to identify the risk of disease progression at an earlier stage, thus guiding more timely interventions. In our study, we found that the ASD progressively shortens as the disease progresses, with an average reduction of 2.45% per month, which provides new evidence of disease progression. This may be due to increased fibrosis and volume loss in progressive IPF, leading to a reduction in the anterior-posterior anatomical distance of the thorax. This may also be related to variations in the patient’s inspiratory volume. Robbie et al. [24]. found that the aortic sternal distance specifically decreased by 25% per year, providing evidence of disease progression. This aligns with our findings.

Currently, quantitative chest CT techniques are more widely used to assess the severity of emphysema in patients with chronic obstructive pulmonary disease [25, 26]. However, there are fewer studies related to quantitative chest CT techniques in the field of interstitial lung disease. Many visual scoring systems have been used to assess the severity of fibrotic lung disease [27]. However, these methods are time-consuming, labor-intensive, and subjective, in addition to having poor interobserver variability. The quantitative CT analysis of images of patients with IPF not only takes little time and is reproducible but has the ability to quantify the data generated, and has many applications in future studies of this disease [28].

Despite its strengths, this study also has some limitations. First, this was a retrospective study with a small sample size study that included clinically indicated CT examinations, which may have led to the inclusion of patients with more advanced disease, who are more susceptible to bias influenced by their subjective wishes. Second, the differentiation between IPF and other interstitial lung diseases often relies on the honeycombing signs. However, the threshold segmentation method used in this study is incapable of quantifying honeycombing appearances. Third, the assessment of disease progression in this study primarily relied on semi-quantitative/visual analysis, lacking clinical standards and data. In our next study, we will further follow-up the cases, incorporate more clinical data, and conduct a multicenter, large-sample study to delve into the role of quantitative CT analysis in the prognosis of patients with IPF and the value of its application in other interstitial lung diseases.

Conclusions

In conclusion, we have demonstrated that quantitative CT analysis can be used for the diagnosis of IPF and can assess the impairment of lung function, and the reduction of ASD can provide evidence of disease progression. Quantitative chest CT is of great value in the diagnosis, assessment, and prognosis of IPF because of its advantages of noninvasiveness, quantification, objectivity, simplicity, and reliability, and it is worthwhile to promote its use in clinical practice.

Abbreviations

IPF Idiopathic pulmonary fibrosis

PFT Pulmonary function test

BMI Body mass index

FEV1 Forced expiratory volume in first second

FVC Forced vital capacity

TLC Total lung capacity

DLCO Carbon monoxide diffusing capacity

MVV Maximum ventilation volume

ASD Aortic-to-sternal distance

Author contributions

ZH analyzed and interpreted the patient data and was a major contributor in writing the manuscript. LX, ZX and YY analyzed some of the patient data. ZC provided technical support. ZJ proofread the manuscript. All authors read and approved the final manuscript.

Funding

Beijing Kanghua Traditional Chinese and Western Medicine Development Foundation (No. KH–2022–DXJJ–022).

Data availability

The datasets used in the present study are available from the first author and corresponding authors on reasonable request.

Declarations

Ethics approval and consent to participate

The study received approval from the Hospital’s Ethics Committee (Ethics No. YJSKY2023-297). Verbal and written details were relayed to all participants, and written consent was secured from all.

Clinical trial number

As this study involved standard clinical procedures and assessments without an experimental treatment protocol, it did not require registration with a public clinical trials registry.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Althobiani MA Russell A-M Jacob J Ranjan Y Folarin AA Hurst JR Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment Front Med 2024 11 1296890 10.3389/fmed.2024.1296890
Althobiani MA, Russell A-M, Jacob J, Ranjan Y, Folarin AA, Hurst JR, et al. Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. Front Med. 2024;11:1296890.10.3389/fmed.2024.1296890
2. Martinez FJ Collard HR Pardo A Raghu G Richeldi L Selman M Idiopathic pulmonary fibrosis Nat Rev Dis Primer 2017 3 17074 10.1038/nrdp.2017.74
Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primer. 2017;3:17074.10.1038/nrdp.2017.74
3. Maher TM Bendstrup E Dron L Langley J Smith G Khalid JM Global incidence and prevalence of idiopathic pulmonary fibrosis Respir Res 2021 22 197 10.1186/s12931-021-01791-z 34233665
Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021;22:197.34233665 10.1186/s12931-021-01791-z
4. Sverzellati N Highlights of HRCT imaging in IPF Respir Res 2013 14 Suppl 1 S3 10.1186/1465-9921-14-S1-S3 23734841
Sverzellati N. Highlights of HRCT imaging in IPF. Respir Res. 2013;14(Suppl 1):S3.23734841 10.1186/1465-9921-14-S1-S3
5. Graham BL Steenbruggen I Miller MR Barjaktarevic IZ Cooper BG Hall GL Standardization of Spirometry 2019 Update. An official American Thoracic Society and European Respiratory Society Technical Statement Am J Respir Crit Care Med 2019 200 e70 88 10.1164/rccm.201908-1590ST 31613151
Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200:e70–88.31613151 10.1164/rccm.201908-1590ST
6. Chen A Karwoski RA Gierada DS Bartholmai BJ Koo CW Quantitative CT analysis of diffuse lung disease Radiographics 2020 40 28 43 10.1148/rg.2020190099 31782933
Chen A, Karwoski RA, Gierada DS, Bartholmai BJ, Koo CW. Quantitative CT analysis of diffuse lung disease. Radiographics. 2020;40:28–43.31782933 10.1148/rg.2020190099
7. Salisbury ML Lynch DA Van Beek EJR Kazerooni EA Guo J Xia M Idiopathic pulmonary fibrosis: the Association between the adaptive multiple features method and fibrosis outcomes Am J Respir Crit Care Med 2017 195 921 9 10.1164/rccm.201607-1385OC 27767347
Salisbury ML, Lynch DA, Van Beek EJR, Kazerooni EA, Guo J, Xia M, et al. Idiopathic pulmonary fibrosis: the Association between the adaptive multiple features method and fibrosis outcomes. Am J Respir Crit Care Med. 2017;195:921–9.27767347 10.1164/rccm.201607-1385OC
8. Ohkubo H Kanemitsu Y Uemura T Takakuwa O Takemura M Maeno K Normal lung quantification in Usual interstitial pneumonia pattern: the impact of threshold-based Volumetric CT Analysis for the staging of idiopathic pulmonary fibrosis PLoS ONE 2016 11 e0152505 10.1371/journal.pone.0152505 27031615
Ohkubo H, Kanemitsu Y, Uemura T, Takakuwa O, Takemura M, Maeno K, et al. Normal lung quantification in Usual interstitial pneumonia pattern: the impact of threshold-based Volumetric CT Analysis for the staging of idiopathic pulmonary fibrosis. PLoS ONE. 2016;11:e0152505.27031615 10.1371/journal.pone.0152505
9. Stefano A Gioè M Russo G Palmucci S Torrisi SE Bignardi S Performance of Radiomics Features in the quantification of idiopathic pulmonary fibrosis from HRCT Diagnostics 2020 10 306 10.3390/diagnostics10050306 32429182
Stefano A, Gioè M, Russo G, Palmucci S, Torrisi SE, Bignardi S, et al. Performance of Radiomics Features in the quantification of idiopathic pulmonary fibrosis from HRCT. Diagnostics. 2020;10:306.32429182 10.3390/diagnostics10050306
10. Ash SY Harmouche R Vallejo DLL Villalba JA Ostridge K Gunville R Densitometric and local histogram based analysis of computed tomography images in patients with idiopathic pulmonary fibrosis Respir Res 2017 18 45 10.1186/s12931-017-0527-8 28264721
Ash SY, Harmouche R, Vallejo DLL, Villalba JA, Ostridge K, Gunville R, et al. Densitometric and local histogram based analysis of computed tomography images in patients with idiopathic pulmonary fibrosis. Respir Res. 2017;18:45.28264721 10.1186/s12931-017-0527-8
11. Shin Matsuoka Objective quantitative CT evaluation using different attenuation ranges in patients with pulmonary fibrosis: correlations with visual scores Int J Respiratory Pulmonary Med 2016 3 2 0 0 10.23937/2378-3516/1410049
Shin Matsuoka. Objective quantitative CT evaluation using different attenuation ranges in patients with pulmonary fibrosis: correlations with visual scores. Int J Respiratory Pulmonary Med. 2016;3(2):0–0. 10.23937/2378-3516/1410049.10.23937/2378-3516/1410049
12. Oldham JM Noth I Idiopathic pulmonary fibrosis: early detection and referral Respir Med 2014 108 819 29 10.1016/j.rmed.2014.03.008 24746629
Oldham JM, Noth I. Idiopathic pulmonary fibrosis: early detection and referral. Respir Med. 2014;108:819–29.24746629 10.1016/j.rmed.2014.03.008
13. Hewson T McKeever TM Gibson JE Navaratnam V Hubbard RB Hutchinson JP Timing of onset of symptoms in people with idiopathic pulmonary fibrosis Thorax 2018 73 683 5 10.1136/thoraxjnl-2017-210177
Hewson T, McKeever TM, Gibson JE, Navaratnam V, Hubbard RB, Hutchinson JP. Timing of onset of symptoms in people with idiopathic pulmonary fibrosis. Thorax. 2018;73:683–5.10.1136/thoraxjnl-2017-210177
14. Ostridge K Wilkinson TMA Present and future utility of computed tomography scanning in the assessment and management of COPD Eur Respir J 2016 48 216 28 10.1183/13993003.00041-2016 27230448
Ostridge K, Wilkinson TMA. Present and future utility of computed tomography scanning in the assessment and management of COPD. Eur Respir J. 2016;48:216–28.27230448 10.1183/13993003.00041-2016
15. Oldham JM Lee CT Wu Z Bowman WS Pugashetti JV Dao N Lung function trajectory in progressive fibrosing interstitial lung disease Eur Respir J 2022 59 2101396 10.1183/13993003.01396-2021 34737223
Oldham JM, Lee CT, Wu Z, Bowman WS, Pugashetti JV, Dao N, et al. Lung function trajectory in progressive fibrosing interstitial lung disease. Eur Respir J. 2022;59:2101396.34737223 10.1183/13993003.01396-2021
16. Reichmann WM Yu YF Macaulay D Wu EQ Nathan SD Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis BMC Pulm Med 2015 15 167 10.1186/s12890-015-0161-5 26714746
Reichmann WM, Yu YF, Macaulay D, Wu EQ, Nathan SD. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. BMC Pulm Med. 2015;15:167.26714746 10.1186/s12890-015-0161-5
17. Raghu G Remy-Jardin M Myers JL Richeldi L Ryerson CJ Lederer DJ Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline Am J Respir Crit Care Med 2018 198 e44 68 10.1164/rccm.201807-1255ST 30168753
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44–68.30168753 10.1164/rccm.201807-1255ST
18. Koo HJ Lee SM Seo JB Lee SM Kim N Oh SY Prediction of pulmonary function in patients with chronic obstructive Pulmonary Disease: correlation with quantitative CT parameters Korean J Radiol 2019 20 683 10.3348/kjr.2018.0391 30887750
Koo HJ, Lee SM, Seo JB, Lee SM, Kim N, Oh SY, et al. Prediction of pulmonary function in patients with chronic obstructive Pulmonary Disease: correlation with quantitative CT parameters. Korean J Radiol. 2019;20:683.30887750 10.3348/kjr.2018.0391
19. Koh SY Lee JH Park H Goo JM Value of CT quantification in progressive fibrosing interstitial lung disease: a deep learning approach Eur Radiol 2023 10.1007/s00330-023-10483-9 38085286
Koh SY, Lee JH, Park H, Goo JM. Value of CT quantification in progressive fibrosing interstitial lung disease: a deep learning approach. Eur Radiol. 2023. 10.1007/s00330-023-10483-9.38085286 10.1007/s00330-023-10483-9
20. Richeldi L Ryerson CJ Lee JS Wolters PJ Koth LL Ley B Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis Thorax 2012 67 407 11 10.1136/thoraxjnl-2011-201184 22426899
Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012;67:407–11.22426899 10.1136/thoraxjnl-2011-201184
21. Andersson H Aaløkken TM Günther A Mynarek GK Garen T Lund MB Pulmonary involvement in the antisynthetase syndrome: a comparative cross-sectional study J Rheumatol 2016 43 1107 13 10.3899/jrheum.151067 27036381
Andersson H, Aaløkken TM, Günther A, Mynarek GK, Garen T, Lund MB, et al. Pulmonary involvement in the antisynthetase syndrome: a comparative cross-sectional study. J Rheumatol. 2016;43:1107–13.27036381 10.3899/jrheum.151067
22. Du K Zhu Y Mao R Qu Y Cui B Ma Y Medium-long term prognosis prediction for idiopathic pulmonary fibrosis patients based on quantitative analysis of fibrotic lung volume Respir Res 2022 23 372 10.1186/s12931-022-02276-3 36550474
Du K, Zhu Y, Mao R, Qu Y, Cui B, Ma Y, et al. Medium-long term prognosis prediction for idiopathic pulmonary fibrosis patients based on quantitative analysis of fibrotic lung volume. Respir Res. 2022;23:372.36550474 10.1186/s12931-022-02276-3
23. Jensen K Nizamutdinov D Guerrier M Afroze S Dostal D Glaser S General mechanisms of nicotine-induced fibrogenesis FASEB J 2012 26 4778 87 10.1096/fj.12-206458 22906950
Jensen K, Nizamutdinov D, Guerrier M, Afroze S, Dostal D, Glaser S. General mechanisms of nicotine-induced fibrogenesis. FASEB J. 2012;26:4778–87.22906950 10.1096/fj.12-206458
24. Robbie H Wells AU Fang C Jacob J Walsh SLF Nair A Serial decline in lung volume parameters on computed tomography (CT) predicts outcome in idiopathic pulmonary fibrosis (IPF) Eur Radiol 2022 32 2650 60 10.1007/s00330-021-08338-2 34716781
Robbie H, Wells AU, Fang C, Jacob J, Walsh SLF, Nair A, et al. Serial decline in lung volume parameters on computed tomography (CT) predicts outcome in idiopathic pulmonary fibrosis (IPF). Eur Radiol. 2022;32:2650–60.34716781 10.1007/s00330-021-08338-2
25. Konietzke P Wielpütz MO Wagner WL Wuennemann F Kauczor H-U Heussel CP Quantitative CT detects progression in COPD patients with severe emphysema in a 3-month interval Eur Radiol 2020 30 2502 12 10.1007/s00330-019-06577-y 31965260
Konietzke P, Wielpütz MO, Wagner WL, Wuennemann F, Kauczor H-U, Heussel CP, et al. Quantitative CT detects progression in COPD patients with severe emphysema in a 3-month interval. Eur Radiol. 2020;30:2502–12.31965260 10.1007/s00330-019-06577-y
26. Schroeder JD McKenzie AS Zach JA Wilson CG Curran-Everett D Stinson DS Relationships between airflow obstruction and quantitative CT measurements of emphysema, air trapping, and airways in subjects with and without chronic obstructive pulmonary disease Am J Roentgenol 2013 201 W460 70 10.2214/AJR.12.10102 23971478
Schroeder JD, McKenzie AS, Zach JA, Wilson CG, Curran-Everett D, Stinson DS, et al. Relationships between airflow obstruction and quantitative CT measurements of emphysema, air trapping, and airways in subjects with and without chronic obstructive pulmonary disease. Am J Roentgenol. 2013;201:W460–70.23971478 10.2214/AJR.12.10102
27. Kishaba T Maeda A Yamazato S Nabeya D Yamashiro S Nagano H Radiological and physiological predictors of IPF Mortality Med (Mex) 2021 57 1121
Kishaba T, Maeda A, Yamazato S, Nabeya D, Yamashiro S, Nagano H. Radiological and physiological predictors of IPF Mortality. Med (Mex). 2021;57:1121.
28. Chung JH Adegunsoye A Cannon B Vij R Oldham JM King C Differentiation of idiopathic pulmonary fibrosis from connective tissue disease-related interstitial lung Disease using quantitative imaging J Clin Med 2021 10 2663 10.3390/jcm10122663 34204184
Chung JH, Adegunsoye A, Cannon B, Vij R, Oldham JM, King C, et al. Differentiation of idiopathic pulmonary fibrosis from connective tissue disease-related interstitial lung Disease using quantitative imaging. J Clin Med. 2021;10:2663.34204184 10.3390/jcm10122663
